CNBC Fast Money
2026-05-22 · Hosted by Melissa Lee · CNBC
Executive Summary
CNBC Fast Money focused on three major themes: Walmart’s 7% drop (worst day since November 2023) and what its cautious consumer commentary means for the broader economy, the AI IPO race with OpenAI preparing a confidential filing as early as Friday and the SpaceX S1 deep-dive, and healthcare sector catalysts including Eli Lilly’s retotrutide efficacy data and ASCO oncology previews. The show also discussed the US government’s $2 billion quantum computing investment, Spotify’s 13% pop on investor day, and a CNBC Disruptor 50 feature on AI-driven drug discovery firm Iambic Therapeutics. The Dow closed at a record high for the first time since February, up 276 points.
Key Stories & Changes
1. Walmart’s Consumer Warning and Retail Dispersion
Walmart fell 7% — worst day since November 2023 — on disappointing full-year guidance
CFO commentary: fuel prices have increased since Q1 guidance; lower-income consumer “navigating financial distress”; K-shaped economy evident across customer cohorts
Gallons per pump below 10 for the first time since 2022 — a signal of consumer stress at the pump
Higher-income consumer remains strong; trade-down benefit from affluents switching to Walmart partly offsets lower-income weakness
Advertising revenue up 38% (representing ~25% of operating income) cited as a key structural positive
Desk debate: Guy Adami (bullish) — environment Walmart wins in, expects bounce similar to prior pullbacks; Dan Nathan (cautious) — margin compression, inventory up 9% vs. 7.1% sales growth, high valuation; Julie Beal (neutral) — long-term opportunity to attract new customers, but margin compression near-term; Steve Grasso (cautious) — Amazon cheaper on valuation with AI kicker
Former Walmart US CEO Bill Simon: Quarter was “good” despite reaction; online sales growth exceeded total US same-store growth (6.5% contribution from e-commerce); affluent customers remaining “sticky”
Target flagged as potentially better opportunity: lower valuation, more upside if turnaround continues; Target same-store sales rose 5.6%; traffic up 4.4%
Ross Stores strong beat: same-store sales +17% vs. 9.4% est.; no tariff headwinds as domestic off-price retailer
Ralph Lauren: +13% on earnings; China sales grew +50% in quarter; luxury high-end consumer strong
Kroger: CEO pressured at White House event to commit to lowering grocery prices
2. The AI IPO Race: OpenAI, SpaceX, Anthropic
OpenAI preparing confidential IPO filing as early as Friday; targeting September listing
OpenAI Q1 revenue: ~$6 billion; Anthropic Q2 revenue: ~$10.9 billion (first profitable quarter, tops all of 2025 annual revenue)
SpaceX S1 discussed: revenue/loss near parity; all three companies combined estimated at ~$5–6 trillion market cap, all substantially unprofitable
Desk concern: Julie Beal noted OpenAI CFO was “not ready” to file publicly due to concerns about financial quality; rushing to market to beat Anthropic creates disclosure risk
Dan Nathan: these IPOs are “wildly unprofitable” at scale never seen in S&P 500/Nasdaq history; AI CapEx depreciation on 2-4 year cycles makes EBITDA metrics misleading; compared unfavorably to Amazon’s early years because AI hardware depreciates faster than telecom/rail infrastructure
Guy Adami: parallels to Amazon — people forget Amazon fell ~90% before becoming the company it is today
3. Quantum Computing: $2 Billion Government Bet
US government announced $2 billion in grants to 9 quantum firms including IonQ, Inflection, D-Wave, Arque, Global Foundries, IBM
IBM: best day in over a year (~single-handedly drove Dow to record); receiving $1 billion in funding; plans chip foundry spinoff
Steve Grasso: owns IonQ and Inflection; argues government backing brings forward the timeline from 10-15 years to 5-7 years; compares quantum to “where AI was in 2018 with a very strong tailwind”
Concern raised: government picking winners and losers has a mixed track record (Intel, MP Materials cited as cautionary examples)
4. Eli Lilly’s Next-Gen Weight Loss Data and ASCO Preview
Retotrutide (triple agonist): 28% average body weight loss over 80 weeks at highest dose; ~70 pounds average; nearly half of patients lost 30%+ (approaching bariatric surgery levels)
Side effects: ~11% on highest dose discontinued due to GI issues
Analyst Jared Holtz (Mizuho): results in line with expectations of 25-30%; more excited about Novo Nordisk’s oral wagovi pill — over 1 million patients now on it and being “completely overlooked”
Steve Grasso: broader pharma (Merck, J&J, BMS) all up ~10% each; argues market “moving away from the GLP story”
ASCO preview: Revolution Medicines (pancreatic cancer phase 3) is street’s most anticipated; Summit Therapeutics (lung cancer bi-specific antibody OS data) also flagged
BioNTech up ~6% on bi-specific antibody lung cancer data; Merck up 3% on combination therapy with Keytruda showing 65% reduction in disease progression and death vs. Keytruda alone
Grasso’s final trade: Merck — Keytruda combo therapies extending patent cliff life
5. Spotify Investor Day
Spotify jumped 13% on first investor day in 4 years; stock still down 20%+ over past year on AI disruption fears
Partnership with Universal Music Group to enable AI remixes/covers of existing artist catalogs (voluntary opt-in)
New product: concert ticket reservation for premium users — holds tickets for superfans before general sale
2030 targets: mid-teens revenue CAGR, 35-40% gross profit, 20%+ operating profit; long-term goal of 1 billion subscribers, $100 billion revenue
Biggest subscriber intake in Spotify history announced “just last week” at 20th anniversary event
Dan Nathan: bullish; AI tailwind for recommendations and content creation; margin expansion story compelling
6. Iambic Therapeutics (CNBC Disruptor 50)
AI-driven drug discovery platform; has gotten drugs to clinic in a third of industry average time
Partnerships with Lundbeck, Revolution Medicines, Decada providing revenue
CEO Tom Miller: AI allows exploration of molecular search space rapidly; already seeing AI replace early experimental phases and avoid dead ends
Grasso: excited about small-cap biotech with AI-driven discovery broadly
Trends Identified
1. The Consumer Is Bifurcated, Not Broken
Walmart’s results make clear that the US consumer story is not monolithic. Higher-income consumers continue to spend with confidence — supporting luxury retailers like Ralph Lauren (China sales +50%), Williams-Sonoma, and Abercrombie — while lower-income consumers face acute pressure from $4.50 gas and diminishing tax refund buffers. The key risk is when that buffer exhausts: the end of Q1 tax refund boost and persistent fuel costs could compress the middle consumer cohort in Q2, making trade-down dynamics potentially even more extreme.
2. AI Lab IPOs Are Rewriting the Rules for Public Market Valuation
The Fast Money desk collectively struggled to value OpenAI, Anthropic, or SpaceX using conventional metrics — and that may be the point. All three companies are being priced on exponential growth trajectories and TAM claims that dwarf their current revenues. The concern raised by Julie Beal — that AI CapEx depreciates on 2-4 year cycles, making EBITDA misleading — is the most structurally important analytical point: the capital efficiency profile of AI companies is fundamentally different from previous infrastructure waves.
3. Quantum Computing Timeline Compression Is Accelerating
Steve Grasso’s analogy — “quantum is where AI was in 2018” — captures an important inflection. Government validation, combined with private equity enthusiasm, is compressing the perceived timeline for commercial quantum applications from more than a decade to five to seven years. IBM’s position as the frontrunner with 75 active systems and its planned chip foundry gives it a structural advantage as the sector transitions from pure research to early commercial deployment.
4. The GLP-1 Market Is Maturing and Fragmenting
The retotrutide data confirms Lilly’s leadership in the high-efficacy injectable segment, but analysts are pointing to Novo Nordisk’s oral wagovi (now exceeding 1 million patients) as the more overlooked opportunity. The market is shifting from a simple Lilly vs. Novo competition to a segmented landscape: bariatric-equivalent efficacy for morbidly obese patients (retotrutide), mainstream oral treatment (wagovi pill), and combination therapies that extend patent lifespans (Merck + Keytruda combos). The real innovation edge may be in patient selection and sequencing rather than raw efficacy. —-
Sentiment Analysis
Overall Market Sentiment: Mixed — Record Close Masks Underlying Stress
The Dow set a record but the consumer picture is increasingly K-shaped, and the AI IPO wave raises valuation questions that the desk couldn’t resolve. Healthcare was a bright spot; retail showed significant dispersion between winners (Ross, Ralph Lauren) and losers (Walmart).
Risk Factors Highlighted
Lower-income consumer exhaustion: Gallons per pump below 10 for first time since 2022; tax refund buffer fades in Q2; K-shaped stress intensifying
OpenAI IPO quality concerns: CFO reportedly flagged concerns about financial readiness; rushing market debut ahead of Anthropic raises disclosure and credibility risk
AI CapEx depreciation cycle: Depreciation on 2-4 year GPU cycles makes EBITDA misleading; differs fundamentally from telecom/rail infrastructure buildouts
SpaceX/OpenAI/Anthropic entering indices unprofitably: Combined ~$5-6 trillion market cap; will displace existing profitable companies in passive indices
Walmart margin compression: Energy costs not passed through; inventory up 9% vs. 7.1% sales growth; multiple at 40x PE leaves little room for misses
Target vulnerable to consumer moderation: Discretionary mix and slower turnaround pace leaves it exposed if high-income spending softens
Government quantum investment crowding out private discipline: Risk that government backing creates inefficiency; mixed precedent (Intel, MP Materials cited)
GLP-1 side effect profile: 11% discontinuation rate on highest retotrutide dose; limits addressable population for best-in-class drug
This episode was covered in today’s The Market Signal — 2026-05-22, a cross-source synthesis of multiple podcast reports.